DSIP
A peptide discussed for sleep-related and neuroregulatory interest, though its evidence base is far less concrete than vendor listings suggest.
Also referenced as: Delta Sleep-Inducing Peptide
This name primarily lives in the research market and should not be read like an approved pharmaceutical product.
This profile is grouped by its dominant research and market lane, not by vendor shelf placement.
Delta Sleep-Inducing Peptide
No FDA label signal · 0 trials · 462 PubMed results
What DSIP is
DSIP stands for delta sleep-inducing peptide. It has been part of peptide and nootropic discussions for years, usually framed around sleep quality, stress, or neuroregulatory effects.
Why it matters
It is a good example of a compound with strong market persistence despite limited mainstream clinical presence. That makes it useful for understanding how peptide demand and evidence often move at different speeds.
Regulatory context
DSIP is not an FDA-approved sleep medicine in the United States. It should be treated as a research-market entry.
Practical reading note
This is one of the categories where vendor popularity can easily outrun evidence clarity, so careful skepticism is warranted.